The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade

David A. Schaer; Richard P. Beckmann; Jack A. Dempsey; Lysiane Huber; Amelie Forest; Nelusha Amaladas; Yanxia Li; Ying Cindy Wang; Erik R. Rasmussen; Darin Chin; Andrew Capen; Carmine Carpenito; Kirk A. Staschke; Linda A. Chung; Lacey M. Litchfield; Farhana F. Merzoug; Xueqian Gong; Philip W. Iversen; Sean Buchanan; Alfonso De Dios; Ruslan D. Novosiadly; Michael Kalos

doi:10.1016/j.celrep.2018.02.053

journal article Open Access Mar 01, 2018

The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade

David A. Schaer Richard P. Beckmann Jack A. Dempsey Lysiane Huber Amelie Forest Nelusha Amaladas Yanxia Li

Ying Cindy Wang Erik R. Rasmussen Darin Chin Andrew Capen Carmine Carpenito Kirk A. Staschke

Linda A. Chung Lacey M. Litchfield Farhana F. Merzoug Xueqian Gong Philip W. Iversen Sean Buchanan

Alfonso De Dios Ruslan D. Novosiadly Michael Kalos

Cell Reports Vol. 22 No. 11 pp. 2978-2994 · Elsevier BV

View at Publisher Save 10.1016/j.celrep.2018.02.053

Topics

No keywords indexed for this article. Browse by subject →

References

36

[1]

Antony "CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells" J. Immunol. (2005) 10.4049/jimmunol.174.5.2591

[2]

Appleman "CD28 costimulation mediates T cell expansion via IL-2-independent and IL-2-dependent regulation of cell cycle progression" J. Immunol. (2000) 10.4049/jimmunol.164.1.144

[3]

Araki "mTOR regulates memory CD8 T-cell differentiation" Nature (2009) 10.1038/nature08155

[4]

Castle "Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma" BMC Genomics (2014) 10.1186/1471-2164-15-190

[5]

The Senescence-Associated Secretory Phenotype: The Dark Side of Tumor Suppression

Jean-Philippe Coppé, Pierre-Yves Desprez, Ana Krtolica et al.

Annual Review of Pathology: Mechanisms of Disease 2010 10.1146/annurev-pathol-121808-102144

[6]

Cristofanilli Lancet Oncol. (2016) 10.1016/s1470-2045(15)00613-0

[7]

Deng "CDK4/6 inhibition augments anti-tumor immunity by enhancing T cell activation" Cancer Disc. (2018) 10.1158/2159-8290.cd-17-0915

[8]

Ebert "MAP kinase inhibition promotes T cell and anti-tumor activity in combination with PD-L1 checkpoint blockade" Immunity (2016) 10.1016/j.immuni.2016.01.024

[9]

Finn "PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro" Breast Cancer Res. (2009) 10.1186/bcr2419

[10]

Palbociclib and Letrozole in Advanced Breast Cancer

Richard S. Finn, Miguel Martin, Hope S. Rugo et al.

New England Journal of Medicine 2016 10.1056/nejmoa1607303

[11]

Goel "CDK4/6 inhibition triggers anti-tumour immunity" Nature (2017) 10.1038/nature23465

[12]

Gotwals "Prospects for combining targeted and conventional cancer therapy with immunotherapy" Nat. Rev. Cancer (2017) 10.1038/nrc.2017.17

[13]

Hallmarks of Cancer: The Next Generation

Douglas Hanahan, Robert A. Weinberg

Cell 2011 10.1016/j.cell.2011.02.013

[14]

Hermann-Kleiter "NFAT pulls the strings during CD4+ T helper cell effector functions" Blood (2010) 10.1182/blood-2009-10-233585

[15]

Hortobagyi "Ribociclib as first-line therapy for HR-positive, advanced breast cancer" N. Engl. J. Med. (2016) 10.1056/nejmoa1609709

[16]

Jure-Kunkel "Synergy between chemotherapeutic agents and CTLA-4 blockade in preclinical tumor models" Cancer Immunol. Immunother. (2013) 10.1007/s00262-013-1451-5

[17]

Koneru "Defective proximal TCR signaling inhibits CD8+ tumor-infiltrating lymphocyte lytic function" J. Immunol. (2005) 10.4049/jimmunol.174.4.1830

[18]

BRAF Inhibitor Vemurafenib Improves the Antitumor Activity of Adoptive Cell Immunotherapy

Richard C. Koya, Stephen Mok, Nicholas Otte et al.

Cancer Research 2012 10.1158/0008-5472.can-11-2837

[19]

Macian "NFAT proteins: key regulators of T-cell development and function" Nat. Rev. Immunol. (2005) 10.1038/nri1632

[20]

Mosely "Rational selection of syngeneic preclinical tumor models for immunotherapeutic drug discovery" Cancer Immunol. Res. (2017) 10.1158/2326-6066.cir-16-0114

[21]

Muñoz-Espín "Cellular senescence: from physiology to pathology" Nat. Rev. Mol. Cell Biol. (2014) 10.1038/nrm3823

[22]

Murphy "The role of CDK4/6 inhibition in breast cancer" Oncologist (2015) 10.1634/theoncologist.2014-0443

[23]

O’Leary "Treating cancer with selective CDK4/6 inhibitors" Nat. Rev. Clin. Oncol. (2016) 10.1038/nrclinonc.2016.26

[24]

Antitumour actions of interferons: implications for cancer therapy

Belinda S. Parker, Jai Rautela, Paul J. Hertzog

Nature Reviews Cancer 2016 10.1038/nrc.2016.14

[25]

Patnaik "Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non-small cell lung cancer, and other solid tumors" Cancer Discov. (2016) 10.1158/2159-8290.cd-16-0095

[26]

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Martin Reck, Delvys Rodríguez-Abreu, Andrew G. Robinson et al.

New England Journal of Medicine 2016 10.1056/nejmoa1606774

[27]

Ribas "Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma" J. Clin. Oncol. (2015) 10.1200/jco.2015.33.15_suppl.3003

[28]

Rockwell "Characteristics of a serially transplanted mouse mammary tumor and its tissue-culture-adapted derivative" J. Natl. Cancer Inst. (1972)

[29]

Schaer "Detection of intra-tumor self antigen recognition during melanoma tumor progression in mice using advanced multimode confocal/two photon microscope" PLoS ONE (2011) 10.1371/journal.pone.0021214

[30]

Interferon-γ: an overview of signals, mechanisms and functions

Kate Schroder, Paul J Hertzog, Timothy Ravasi et al.

Journal of Leukocyte Biology 2004 10.1189/jlb.0603252

[31]

Sherr "Targeting CDK4 and CDK6: from discovery to therapy" Cancer Discov. (2016) 10.1158/2159-8290.cd-15-0894

[32]

Spitzer "Systemic immunity is required for effective cancer immunotherapy" Cell (2017) 10.1016/j.cell.2016.12.022

[33]

Torres-Guzmán "Preclinical characterization of abemaciclib in hormone receptor positive breast cancer" Oncotarget (2017) 10.18632/oncotarget.17778

[34]

Vonderheide "Immunotherapy for breast cancer: what are we missing?" Clin. Cancer Res. (2017) 10.1158/1078-0432.ccr-16-2569

[35]

Wells "New roles for cyclin-dependent kinases in T cell biology: linking cell division and differentiation" Nat. Rev. Immunol. (2014) 10.1038/nri3625

[36]

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

Jedd D. Wolchok, Axel Hoos, Steven O'Day et al.

Clinical Cancer Research 2009 10.1158/1078-0432.ccr-09-1624

Cited By

395

Efficacy and Safety of CDK4/6 Inhibitors: A Focus on HR+/HER2− Early Breast Cancer

Eva Valentina Klocker, Daniel Egle · 2025

Drugs

CDK4/6 inhibitors in lung cancer: current practice and future directions

Shuoshuo Lv, Jie Yang · 2024

European Respiratory Review

The CDK4/6 inhibitor revolution — a game-changing era for breast cancer treatment

Laura Morrison, Sibylle Loibl · 2023

Nature Reviews Clinical Oncology

Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer

Laura A. Huppert, Ozge Gumusay · 2023

CA: A Cancer Journal for Clinicians

CDK4/6 Inhibitors in Combination Therapies: Better in Company Than Alone: A Mini Review

Gian Luca Rampioni Vinciguerra, Maura Sonego · 2022

Frontiers in Oncology

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions

Ming Yi, Xiaoli Zheng · 2022

Molecular Cancer

Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients

Erez N. Baruch, Ilan Youngster · 2021

Science

Senescent Cells in Cancer Therapy: Friends or Foes?

Boshi Wang, Jaskaren Kohli · 2020

Trends in Cancer

CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy

Anne Y Lai, Jessica A Sorrentino · 2020

Journal for ImmunoTherapy of Cancer

Endocrine and Targeted Therapy for Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer: Insights to Sequencing Treatment and Overcoming Resistance Based on Clinical Trials

Rola El Sayed, Lara El Jamal · 2019

Frontiers in Oncology

Metrics

395

Citations

36

References

Details

Published: Mar 01, 2018
Vol/Issue: 22(11)
Pages: 2978-2994
License: View

Authors

Authors' Affiliations: 1Abramson Family Cancer Research Institute and Department of Pathology and Laboratory Medicine and 2Thoracic Oncology Research Laboratory and Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania

Asper School of Business, University of Manitoba, Winnipeg, Manitoba R3T 5V4, Canada;

Cite This Article

David A. Schaer, Richard P. Beckmann, Jack A. Dempsey, et al. (2018). The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade. Cell Reports, 22(11), 2978-2994. https://doi.org/10.1016/j.celrep.2018.02.053

The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade

You May Also Like